Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer-Reference-Cited by-同舟云学术

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

Published:2021-02-15 Issue: Volume: Page:
ISSN:
Container-title:Poster Spotlight Session Abstracts
language:
Short-container-title:

Author:

Modi Shanu,Saura Cristina,Yamashita Toshinari,Park Yeon Hee,Kim Sung-Bae,Tamura Kenji,Andre Fabrice,Iwata Hiroji,Ito Yoshinori,Tsurutani Junji,Sohn Joohyuk,Denduluri Neelima,Perrin Christophe,Aogi Kenjiro,Tokunaga Eriko,Im Seock-Ah,Lee Keun Seok,Hurvitz Sara A,Cortes Javier,Lee Caleb,Liu Yali,Zhang Lin,Shahidi Javad,Yver Antoine,Baselga Jose,Krop Ian E

Publisher

American Association for Cancer Research

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers;Geburtshilfe und Frauenheilkunde;2024-09

2. Trastuzumab deruxtecan in breast cancer;Critical Reviews in Oncology/Hematology;2024-06

3. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01);Annals of Oncology;2023-12

4. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review;Critical Reviews in Oncology/Hematology;2023-12

5. Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data;Critical Reviews in Oncology/Hematology;2023-12